医学
曲妥珠单抗
肽疫苗
临床试验
单克隆抗体
乳腺癌
肽
免疫疗法
HER2/东北
肿瘤科
内科学
癌症
抗体
免疫学
表位
化学
生物化学
作者
Kevin S. Clive,Josh Tyler,Guy T. Clifton,Jarrod P. Holmes,Sathibalan Ponniah,George E. Peoples,Elizabeth A. Mittendorf
摘要
Abstract Preclinical studies suggest that GP2, a HER2/ neu ‐derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2‐based vaccines are safe and effective in stimulating peptide‐specific immunity. A GP2 peptide vaccine is currently being evaluated in a phase II efficacy trial enrolling breast cancer patients. This article reviews initial studies characterizing GP2, clinical trials investigating GP2‐based vaccines, and novel immunotherapy strategies incorporating GP2 in combination with other peptides or with the monoclonal antibody trastuzumab. J. Surg. Oncol. 2012; 105:452–458. © 2012 Wiley Periodicals, Inc.
科研通智能强力驱动
Strongly Powered by AbleSci AI